Our Mission Assistance Case Studies Press Room IPAO Forum
HOME : IPAO Forum
Please sign in:
Forgot Password
Register >
FORUM CATEGORIES
Commentaries on IP issues by experts from business, academia, science ...
The IP Climate is Changing - What You Should Know
Facing off with a university in court is something no inventor wants to ...
Ethics and technology transfer do not always go hand-in-hand. Share your...
Intellectual property polices may differ from actual practices at your u...






Ethics and Best Practices

Ethics and technology transfer do not always go hand-in-hand. Share your thoughts and experiences here.

Search the Forum
 

When Universities Stand with their Researchers, Everyone Benefits...

Drs. Dennis Liotta, Raymond Schinazi and Woo-Baeg Choi developed two major drugs to fight HIV: lamivudine (3TC) and emtricitabine (FTC) which are the treatment of choice for some 80 percent of all HIV/AIDS patients.

 

For faculty researchers, protecting patent rights is critical for pursuit of subsequent research and licensing to generate funds for further research. How patent rights are determined differs for the U.S. and international rights. In the states, patent ownership is determined by the date of the invention, while international rights are based on the patent filing date.

 

In the case of these HIV drugs, BioChem won the international rights to 3TC, while Emory University, on behalf of its researchers, secured the U.S. patent rights. BioChem licensed its international patents to British pharmaceutical company Glaxo, which then tried to grab a share of the U.S. rights.

 

Emory also held the patent rights for FTC and had licensed it to Burroughs Wellcome, which was later acquired by Glaxo who returned the FTC license to the university, but not critical clinical trial data that should have been returned or destroyed, but was instead used as the basis for Burroughs to seek a patent to use FTC to treat Hepatitis B.

 

To defend its license rights and protect its inventors’ intellectual property Emory sued Glaxo. Unlike some cases, Emory University came to the aid of its researchers, resulting in the preservation of their intellectual property rights and ensuring their continued dedication to the university.

 

This complex patent and litigation controversy was settled out of court after six years and millions of dollars in legal fees. Emory and its researchers kept the rights to both 3TC and FTC and the university received nearly half a billion dollars as well as an ongoing royalty stream.

 

By standing with their inventors, Emory, their researchers and the greater good all benefited. Emory continues to be an international leader in HIV/AIDS research and all of the researchers continue their life saving work.

 

Reply to Topic

 
   

Comments

Comments : 2 - Last Post : Apr 20, 2009 12:39 PM by: gburfield
re: When Universities Stand with their Researchers, Everyone Benefits...
Posted by rowan32: Apr 20, 2009 11:21 AM

Hoorah for Emory! It is so wonderful to read about a university working with instead of against their researchers.

re: When Universities Stand with their Researchers, Everyone Benefits...
Posted by gburfield: Apr 20, 2009 12:39 PM

Emory and its researchers are doing such great work for HIV sufferers. The impact of these drugs has been felt worldwide. These developments have impacted me personally as I have a friend and a family member suffering from this dreadful illness and who have received therapy developed by these brave inventors. It is heartening to read that Emory is investing its profits back into HIV research and not into frivolous expenditures.

 
IP Advocate.org Copyright 2018
                 
 
 
 


You are about to leave IPAdvocate.org and go to an outside website.

IPAdvocate.org does not control any outside website and is not responsible

for content, performance or policies, including Privacy Policy.

Thank you for visiting IPAdvocate.org.